Sugi Predict

Sugi Predict / Compounds / SCHEMBL2464877

SCHEMBL2464877

SCHEMBL2464877

CC(C)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 20/20 1.00
▸ PIK3CA P42336 20/20 1.00
▸ PIK3CB P42338 20/20 1.00
▸ PIK3CG P48736 19/20 1.00
▸ ABL1 P00519 16/20 1.00
▸ EGFR P00533 16/20 1.00
▸ HCK P08631 16/20 1.00
▸ SRC P12931 16/20 1.00
▸ KDR P35968 16/20 1.00
▸ MTOR P42345 16/20 1.00
▸ EPHB4 P54760 16/20 1.00
▸ PRKDC P78527 16/20 1.00
▸ PI4KB Q9UBF8 15/20 1.00
▸ BACE1 P56817 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605287 0.86 ABL1 (1.00) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL18868086 0.85 ABL1 (0.74) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL129487 0.84 PIK3CD (0.72) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL17582561 0.82 PIK3CD (0.69) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL409057 0.82 SRC (1.00) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL2434152 0.81 SRC (1.00) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL17582610 0.80 PIK3CD (0.66) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL18868082 0.80 SRC (0.74) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL3607753 0.80 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGABL1
SCHEMBL3603461 0.80 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230111917-A1 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2023-04-13 — — US disclosed
EP-2551270-B1 PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2019-06-12 — — EP disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 — — US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 — — US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 — — US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 — — US disclosed
US-8642604-B2 Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-02-04 — — US disclosed
EP-2004654-B1 PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2013-05-22 — — EP disclosed
CN-101506211-B Kinase antagonists UNIV CALIFORNIA 2013-05-22 — — CN disclosed
EP-2551270-A2 PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS The Regents of The University of California (US) 2013-01-30 — — EP disclosed
US-20110301144-A1 Kinase Antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-08 — — US disclosed
EP-2365810-A2 PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2011-09-21 — — EP disclosed
WO-2010065923-A2 PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-06-10 — — WO disclosed
US-20100009963-A1 KINASE ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-01-14 — — US disclosed
US-7585868-B2 Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-09-08 — — US disclosed
CN-101506211-A Kinase antagonists UNIV CALIFORNIA (US) 2009-08-12 — — CN disclosed
EP-2004654-A2 KINASE ANTAGONISTS The Regents of the University of California (US) 2008-12-24 — — EP disclosed
US-20070293516-A1 Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-12-20 — — US disclosed
WO-2007114926-A2 KINASE ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293516-A1 Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine MTOR, PI4KA, PIK3CA PIK3CD 5/4885PIK3CA 3/4885PIK3CB 17/4885
US-20230111917-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 PIK3CD 12/4885PIK3CA 4/4885PIK3CB 21/4885
US-20100009963-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 PIK3CD 12/4885PIK3CA 4/4885PIK3CB 21/4885
US-20110301144-A1 Kinase Antagonists MTOR, RPS6KA3, AKT3 PIK3CD 12/4885PIK3CA 4/4885PIK3CB 21/4885
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 PIK3CD 5/4885PIK3CA 4/4885PIK3CB 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.